Health Research Authority

East of England - Essex Research Ethics Committee
The Old Chapel
Royal Standard Place
Nottingham
NG1 6FS

20 April 2018

Tony Whitehouse
Queen Elizabeth Hospital Birmingham NHS Foundation Trust
Mindelsohn Way
Birmingham
B15 2GW

Dear Whitehouse

Study title:	**STRESS-L: STudy into the REversal of Septic Shock with Landiolol (Beta Blockade)**
REC reference:	**17/EE/0368**
Protocol number:	**STRESS-L**
EudraCT number:	**2017-001785-14**
Amendment number:	**3**
Amendment date:	**19 April 2018**
IRAS project ID:	**213669**

Thank you for submitting the above amendment, which was received on 19 April 2018.

Research site	*Principal Investigator / Local Collaborator*
University Hospitals Bristol NHS Foundation Trust	Dr Jeremy Bewley
Sherwood Forest Hospitals NHS Foundation Trust	Dr Paul Pulak
Taunton and Somerset NHS Foundation Trust	Dr Richard Innes
Portsmouth Hospitals NHS Trust	Dr David Pogson
The Royal Liverpool University Hospital	Dr Ingeborg Welters
Poole Hospital NHS Foundation Trust	Dr Henrik REschreiter
Royal Devon & Exeter NHS Foundation Trust	Dr Charly Gibson
Derby Teaching Hospitals NHS Foundation Trust	Dr David Rogerson
North Bristol NHS Trust, Southmead Hospital	Dr Matt Thomas
City Hospitals Sunderland NHS Foundation Trust	Dr Alistair Roy
University Hospital Southampton NHS Foundation Trust	Dr Rebecca Cusack

The amendment relates solely to the addition of new site(s) and/or investigator(s) within the National Health Service (NHS) or Health and Social Care (HSC) in Northern Ireland. Site-specific assessment (SSA) for any site within the National Health Service (NHS) or Health and Social Care (HSC) in Northern Ireland will form part of the nation specific local processes for that site. Guidance on how to work with sites is provided in the IRAS help section at https://www.myresearchproject.org.uk/help/hlpnhshscr.aspx

On behalf of the Committee, I am pleased to confirm the extension of the favourable opinion to the new site(s) and/or investigator(s), subject to management permission being given by the relevant host organisation prior to the study starting at the site.

Statement of compliance

This Committee is recognised by the United Kingdom Ethics Committee Authority under the Medicines for Human Use (Clinical Trials) Regulations 2004, and is authorised to carry out the ethical review of clinical trials of investigational medicinal products.

The Committee is fully compliant with the Regulations as they relate to ethics committees and the conditions and principles of good clinical practice.

The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK.

17/EE/0368	**Please quote this number on all correspondence**

Yours sincerely



Silje Dybing
REC assistant

Email: NRESCommittee.EastofEngland-Essex@nhs.net

Copy to: *Miss Nafisa Boota*